Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.
about
The role of urotensin II in cardiovascular and renal physiology and diseasesAssociation analysis of urotensin II gene (UTS2) and flanking regions with biochemical parameters related to insulin resistanceRole of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstrictionUrotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenolHuman cardiomyopathy mutations induce myocyte hyperplasia and activate hypertrophic pathways during cardiogenesis in zebrafishThe G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Urotensin II inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signallingGSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivoHemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistulaIdentification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin IIThe peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systemsPotential Clinical Implications of the Urotensin II Receptor Antagonists.The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophyUrotensin-II and the cardiovascular system--the importance of developing modulators.Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S PathwayAn investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat heartsUrotensin-II induces ear flushing in ratsA closer look at the role of urotensin II in the metabolic syndrome.Urotensin-II Immunoreactivity in Normolipidemic and Hyperlipidemic New Zealand White Rabbits Following Balloon Angioplasty and Stenting.Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotidesTherapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?Urotensin II in cardiovascular regulation.Effect of KIOM-79 on Diabetes-Induced Myocardial Fibrosis in Zucker Diabetic Fatty Rats.Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium.PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration.Plasma urotensin II and neurokinin B levels in acute myocardial infarction and stable coronary artery disease.Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes.Role of urotensin II in health and disease.Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.Immunopathogenesis of Myocarditis: The Interplay Between Cardiac Fibroblast Cells, Dendritic Cells, Macrophages and CD4+ T Cells.A novel role of G protein-coupled receptor kinase 5 in urotensin II-stimulated cellular hypertrophy in H9c2UT cells.The role of neuropeptides in adverse myocardial remodeling and heart failure.Urotensin II induces transactivation of the epidermal growth factor receptor via transient oxidation of SHP-2 in the rat renal tubular cell line NRK-52E.Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction.Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease.Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension.Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.Kidney is in trouble with mediators.The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans.
P2860
Q24675590-437EDF05-EBC9-473B-9C0A-F4403D7F215EQ28478002-99674E67-7507-4DA8-B9BE-C498A953E978Q28572971-FE0970D7-412A-4232-B242-554B56E83901Q28573864-AE6E796D-C5FA-4D27-BA4B-5B86C459CB0FQ30500300-1229DBE6-FF22-44AB-9E0F-0495B4A5995BQ33599835-75DA40C0-F592-46FF-AE67-5DADEC63EA59Q33991646-127F6247-3B25-47E9-B68F-AFFFE0AA98CCQ34233981-FC6E080B-8B96-40BE-BFAA-94741399E93EQ34248766-0040F566-3AA8-4B0F-B9AE-70B8F82A59C6Q35047377-7E2CA507-9AFB-46CE-9B8C-FA33676DE369Q35048941-E054BF58-913C-4469-9352-92D15E4F377CQ35100902-09E1F92A-9AC7-4EFB-B538-EF83656D7CF6Q35128456-AD20BE0D-49D4-490A-9D73-FCBE95E14DA7Q35538538-37B4C1A1-1F5B-4166-8C9C-4E3EB1B5A3F6Q35779239-43F09715-B868-49E8-BF76-F1F599286DE7Q35813861-B91E2A7F-95F8-493E-BEE5-0D6DD3089D20Q36224889-5C930F27-D558-484B-B09E-122E4CDAE140Q36357772-A66E818D-B2EA-416B-97D8-04F004478EDFQ36492706-C7A41E92-5C62-472D-B9B5-6C713BE6664DQ36735227-2651B507-648E-4563-9798-F62F073F52E6Q37015817-C4BE65AD-CB4D-493E-BF2D-5B6572591331Q37082781-393BC2B8-3CAA-4602-BE2F-048D0FA8AB73Q37344439-CFFE5BB2-E75C-466A-9E0C-4EE4BA60CFFBQ37353581-AFA5E25C-F346-4C63-A2BC-C50B908683BFQ37394539-99B8CC49-7F6E-4553-9D7F-48573EC600B4Q37422701-7677F749-4DDF-4C77-A1A3-4D53B50E796DQ37680436-3B2E11A1-F9CC-4E2C-B521-C9C695AEF37CQ37728377-5DC83078-B16C-49DA-A225-964F2626195DQ37737495-9B0EDF04-35A5-4838-84C1-4564D481F702Q37970489-176D85E2-5E3E-4CD2-A3F2-0B1CD881CFC2Q38407555-4B82CCEC-B076-4D0E-BB5F-19E1E143200CQ38747134-C2B4AC34-3335-4188-8EC3-1E3FB565B1B1Q39093111-0A48DB32-8CCD-4D6C-B32D-7E8CE21F75FEQ39867550-A847183F-0BB1-4C60-AED5-94C22AA39680Q39939179-703A461C-6361-4202-B3BA-FFD6A709844CQ40122555-BCFC3AA4-BA1B-4945-BA18-09D6A4D0FBB1Q40166897-2E8A07AB-71FE-4784-B368-2E2FEFD3E379Q40430686-B5AE0DA3-1742-47FF-BB26-ADED09B77C1AQ42280581-DFAEBA58-7F3A-44C4-9BF9-2C9C21E0B19FQ42283626-D6D1D1BA-2BB5-4859-8CF6-192592E7AE8F
P2860
Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Direct actions of urotensin II ...... diac fibrosis and hypertrophy.
@en
Direct actions of urotensin II ...... diac fibrosis and hypertrophy.
@nl
type
label
Direct actions of urotensin II ...... diac fibrosis and hypertrophy.
@en
Direct actions of urotensin II ...... diac fibrosis and hypertrophy.
@nl
prefLabel
Direct actions of urotensin II ...... diac fibrosis and hypertrophy.
@en
Direct actions of urotensin II ...... diac fibrosis and hypertrophy.
@nl
P2093
P1433
P1476
Direct actions of urotensin II ...... diac fibrosis and hypertrophy.
@en
P2093
Alex Tzanidis
Darren J Kelly
Dominic J Autelitano
Richard E Gilbert
Ross D Hannan
Walter G Thomas
P304
P356
10.1161/01.RES.0000084382.64418.BC
P50
P577
2003-07-03T00:00:00Z